MedPath

Safety and efficacy of intracranial radiotherapy under immunotherapy against CNS metastases of extensive-stage small cell lung cancer in the real-world setting.

Not Applicable
Recruiting
Conditions
ung Cancer
Registration Number
JPRN-UMIN000041879
Lead Sponsor
Osaka International Cancer Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) The cases which the attending physician has determined ineligible

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety(Grade 3 or higher non-hematological toxicity )
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath